Benefit of intravitreal injections in patients with sub-threshold baseline visual acuity: a retrospective single-centre study.

Journal Information

Full Title: Graefes Arch Clin Exp Ophthalmol

Abbreviation: Graefes Arch Clin Exp Ophthalmol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethical approvalThis study concurs with the 1964 Helsinki declaration and its later amendments, and was approved by our institutional ethics committee of the university of Goettingen (application number is 6/11/20). Conflict of interestNina-Antonia Grimm: Speaker: Novartis AG, Bayer AG, OD-OS GmbH.Sarah Fahimi: No conflict of interest.Fabian Kück: No conflict of interest.Patricia Take: No conflict of interest.Peer Lauermann: No conflict of interest.Anna Nguyen-Hoehl: No conflict of interest.Hans Hoerauf: Consultant: Novartis, Roche Allergan; Speaker: Novartis, Roche, Allergan, Biogen, Alcon, Heidelberg Engeneering; Research projects: Bayer Heath Care, Novartis, Allergan, chengdu Khanghong, Biotec, Hoffmann LaRoche, Samsung, Benevolent, Regeneron, Santen GmbH, Boehringer Ingelheim, Mylan, Appelis; Owner interest in medical products: Novartis, Bayer, 3 M, Roche, Johnson&Johnson, Mediatronis, Abbvie, Pfizer.Nicolas Feltgen: Consultant: Alimera Sciences, Novartis, Roche; Speaker: Allergan, Alimera, Bayer, Heidelberg Engineering, Novartis, Roche.Sebastian Bemme: Speaker: Novartis AG, Bayer AG; Research grant: Novartis AG. Conflict of interest Nina-Antonia Grimm: Speaker: Novartis AG, Bayer AG, OD-OS GmbH. Sarah Fahimi: No conflict of interest. Fabian Kück: No conflict of interest. Patricia Take: No conflict of interest. Peer Lauermann: No conflict of interest. Anna Nguyen-Hoehl: No conflict of interest. Hans Hoerauf: Consultant: Novartis, Roche Allergan; Speaker: Novartis, Roche, Allergan, Biogen, Alcon, Heidelberg Engeneering; Research projects: Bayer Heath Care, Novartis, Allergan, chengdu Khanghong, Biotec, Hoffmann LaRoche, Samsung, Benevolent, Regeneron, Santen GmbH, Boehringer Ingelheim, Mylan, Appelis; Owner interest in medical products: Novartis, Bayer, 3 M, Roche, Johnson&Johnson, Mediatronis, Abbvie, Pfizer. Nicolas Feltgen: Consultant: Alimera Sciences, Novartis, Roche; Speaker: Allergan, Alimera, Bayer, Heidelberg Engineering, Novartis, Roche. Sebastian Bemme: Speaker: Novartis AG, Bayer AG; Research grant: Novartis AG."

Evidence found in paper:

"Funding Open Access funding enabled and organized by Projekt DEAL."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025